“In combining Expedeon and SYGNIS, we are creating a genomics and proteomics specialist with a broad product portfolio,” Pilar de la Huerta, CEO and CFO of SYGNIS, said in a statement.
SYGNIS confirmed that it will fund the deal with the proceeds from a planned offering of up to 20.5 million shares.
Birketts advised on all legal matters with James Allen leading the award-winning corporate team. Assistance on the deal was provided on a range of legal services by colleagues, Karl Pocock (tax) and Lottie Seaborn (share options).
Expedeon CEO Heikki Lanckriet, who will be joining the SYGNIS management team, commented: “The team at Birketts has a first-rate reputation for value, client service and tight project management. Our experience on this transaction and from our relationship in the past completely endorses that view.”
James Allen, corporate partner at Birketts (pictured), said: “I am delighted with the way that our experienced team advised on a range of legal issues during the course of this complicated transaction and have no doubt that the new management team will continue to take SYGNIS from strength-to-strength.”
*******
Matthew Rowe
PR and Communications Manager
Birketts LLP
www.birketts.co.uk
Direct: 01473 406334
Mobile: 07854 833569
__________________________________________________
Birketts advises Expedeon Holdings Limited on its merger with SYGNIS AG
23 June 2016
Birketts, a top 100 law firm, has advised the shareholders of Expedeon Holdings Limited, a privately held UK proteomics company headquartered in Swavesey, near Cambridge, on its merger to SYGNIS AG a German-Spanish stocklisted company that specialises in molecular biology.